Pimozide augmentation therapy in treatment-resistant schizophrenia patients with poor or partial response to clozapine: A retrospective study Klozapin Tedavisine Yeterli Yanıt Alınamayan Tedaviye Dirençli Şizofreni Hastalarında Pimozidle Güçlendirme Yaklaşımı: Geriye Dönük Bir Deǧerlendirme Çalışması
Noropsikiyatri Arsivi, cilt.47, sa.4, ss.302-306, 2010 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 47 Sayı: 4
- Basım Tarihi: 2010
- Doi Numarası: 10.4274/npa.y5570
- Dergi Adı: Noropsikiyatri Arsivi
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.302-306
- Anahtar Kelimeler: Treatmentresistant schizophrenia, augmentation, clozapine, pimozide
- Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
Objective: In this retrospective chart review study we aimed to investigate the effect of pimozide augmentation on schizophrenia patients with poor or partial response to clozapine therapy. Methods: Charts of 17 treatmentresistant schizophrenia patients who had poor or partial response to at least oneyear clozapine therapy and whose treatment was augmented with pimozide were evaluated. Patients who had Clinical Global ImpressionSeverity (CGIS) scores ≥4 and Positive and Negative Syndrome Scale (PANSS) scores ≥72 were considered as poor or partial clozapine responders. The scores on the PANSS, CGI scale, and Extrapyramidal Symptom Rating Scale (ESRS) obtained in the first and the third months of followup were evaluated. Results: The mean age of the 8 female and 9 male (total 17) patients was 32.23±7.87 years, the mean age at onset of illness was 19.94±4.19 years, the mean duration of illness was 12.29±6.12 years, the mean clozapine dose was 500±58.63 mg/day, and the mean pimozide dose was 3.88±0.60 mg /day. The mean PANSS scores decreased from 99.70±13.91 to 3.64±1.27 and the mean CGIS scores decreased from 4.82±0.80 to 3.64±1.27. ESRS scores did not change significantly after the addition of pimozide to the treatment. Conclusion: Pimozide augmentation of clozapine was found to be effective and safe in treatmentresistant schizophrenia patients with poor or partial response to clozapine therapy. © Archives of Neuropsychiatry, published by Galenos Publishing.